BR9913585A - Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável - Google Patents

Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável

Info

Publication number
BR9913585A
BR9913585A BR9913585-0A BR9913585A BR9913585A BR 9913585 A BR9913585 A BR 9913585A BR 9913585 A BR9913585 A BR 9913585A BR 9913585 A BR9913585 A BR 9913585A
Authority
BR
Brazil
Prior art keywords
formulation
botulinum toxin
stable liquid
muscle
cholinergic
Prior art date
Application number
BR9913585-0A
Other languages
English (en)
Inventor
Elizabeth Moyer
Pamela Hirtzer
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of BR9913585A publication Critical patent/BR9913585A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Birds (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)

Abstract

'FORMULAçãO DE TOXINA BOTULINUM FARMACêUTICA LìQUIDA ESTáVEL, MéTODO DE TRATAR UM PACIENTE EM NECESSIDADE DE INIBIçãO DE ENTRADA COLINéRGICA EM UM MúSCULO SELECIONADO, GRUPO DE MúSCULOS, GLâNDULA OU óRGãO, E, USO DE UMA FORMULAçãO DE TOXINA BOTULINUM, LìQUIDA ESTáVEL". A invenção inclui formulações líquidas de toxinas botulinum, que são estáveis à armazenagem em forma líquida em temperaturas de refrigerador padrão por pelo menos 1-2 anos e à armazenagem em temperaturas mais elevadas por pelo menos 6 meses. A invenção também inclui métodos de tratamento empregando tais formulações e usos de tais formulações na manufatura de medicamentos para vários tratamentos terapêuticos e cosméticos.
BR9913585-0A 1998-09-11 1999-09-09 Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável BR9913585A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9987098P 1998-09-11 1998-09-11
PCT/US1999/020912 WO2000015245A2 (en) 1998-09-11 1999-09-09 Stable liquid formulations of botulinum toxin

Publications (1)

Publication Number Publication Date
BR9913585A true BR9913585A (pt) 2001-06-05

Family

ID=22277018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913585-0A BR9913585A (pt) 1998-09-11 1999-09-09 Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável

Country Status (41)

Country Link
US (2) US7211261B1 (pt)
EP (1) EP1112082B2 (pt)
JP (4) JP4557426B2 (pt)
KR (1) KR100699756B1 (pt)
CN (1) CN100438905C (pt)
AP (1) AP1591A (pt)
AR (1) AR022671A1 (pt)
AT (1) ATE221386T1 (pt)
AU (1) AU755556C (pt)
BG (1) BG65555B1 (pt)
BR (1) BR9913585A (pt)
CA (1) CA2342243C (pt)
CO (1) CO5170497A1 (pt)
CU (1) CU23251A3 (pt)
DE (1) DE69902396T3 (pt)
DK (1) DK1112082T4 (pt)
EA (1) EA003367B1 (pt)
EE (1) EE200100140A (pt)
ES (1) ES2181473T5 (pt)
GE (1) GEP20032946B (pt)
HK (1) HK1040927A1 (pt)
HR (1) HRP20010259B1 (pt)
HU (1) HUP0103638A3 (pt)
ID (1) ID28824A (pt)
IL (2) IL141564A0 (pt)
IS (1) IS2381B (pt)
LT (1) LT4959B (pt)
LV (1) LV12684B (pt)
NO (1) NO328898B1 (pt)
NZ (1) NZ509349A (pt)
PL (1) PL200926B1 (pt)
PT (1) PT1112082E (pt)
RS (1) RS50344B (pt)
SA (1) SA99200566B1 (pt)
SI (2) SI1112082T1 (pt)
SK (1) SK286919B6 (pt)
TR (1) TR200100728T2 (pt)
TW (1) TW574036B (pt)
UA (1) UA72477C2 (pt)
WO (1) WO2000015245A2 (pt)
ZA (1) ZA200101709B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174945T3 (es) * 1994-05-09 2002-11-16 William J Binder Toxina de botulinum para la reduccion de cefaleas de migrañas.
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
ES2275992T5 (es) * 2000-02-08 2011-05-18 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
SI1565210T1 (sl) 2002-11-21 2012-07-31 Ira Sanders Klostridialni nevrotoksin za uporabo pri zdravljenju nazalne kongestije
EP1594523B1 (en) * 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmaceutical compositions comprising botulinum toxin and human serum albumin
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
EP1599220B1 (en) * 2003-03-06 2013-07-17 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
SG10201803560WA (en) * 2004-03-03 2018-06-28 Revance Therapeutics Inc Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
KR100852821B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
DE102006019447A1 (de) * 2006-04-24 2007-10-25 Dressler, Dirk, Dr. Markierung von Botulinum Toxin
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
CA2686637A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
EP2315598A1 (en) * 2008-08-05 2011-05-04 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100112005A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
WO2010051038A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CN102300584A (zh) 2008-12-31 2011-12-28 雷文斯治疗公司 可注射的肉毒杆菌毒素制剂
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
BRPI1014253A2 (pt) 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
LT2490986T (lt) * 2009-10-21 2018-11-26 Revance Therapeutics, Inc. Nekompleksinio botulino neurotoksino gryninimo būdai ir sistemos
BR112013018920A2 (pt) * 2011-01-24 2017-11-28 Anterios Inc composições de nanopartículas, formulações destas e seus usos
MX351012B (es) 2011-11-09 2017-09-28 Merz Pharma Gmbh & Co Kgaa Neurotoxinas que exhiben actividad biologica acortada.
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN107205889B (zh) * 2014-09-02 2021-05-11 美国白银有限责任公司 肉毒毒素和胶体银颗粒
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
AU2015381351B2 (en) * 2015-02-03 2020-05-14 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
DK3679946T3 (da) * 2016-05-27 2022-02-07 Ipsen Biopharm Ltd Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
BR112019004929A2 (pt) 2016-09-13 2019-06-04 Allergan Inc composições de toxina clostridial não proteíca
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
US20200179498A1 (en) * 2017-05-18 2020-06-11 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
JP2022514151A (ja) 2018-10-08 2022-02-10 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 神経毒プレフィルドバイアル

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522247A (en) * 1967-11-07 1970-07-28 Pfizer & Co C 2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US4932936A (en) 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of manufacture.
DE69432299T2 (de) 1993-06-10 2003-12-11 Allergan, Inc. Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
AU689115B2 (en) 1993-06-10 1998-03-26 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
GB9315306D0 (en) 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE122008000042I1 (de) 1993-12-28 2009-01-02 Merz Pharma Gmbh & Co Kgaa Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2174945T3 (es) 1994-05-09 2002-11-16 William J Binder Toxina de botulinum para la reduccion de cefaleas de migrañas.
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5562899A (en) 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
US6136551A (en) * 1995-04-24 2000-10-24 Allergan, Inc. Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
DK0773788T3 (da) 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) * 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
CN1057430C (zh) * 1996-10-09 2000-10-18 崔生发 一种生物化学杀鼠剂
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
ES2275992T5 (es) 2000-02-08 2011-05-18 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
US20080118532A1 (en) 2006-06-01 2008-05-22 Atassi M Zouhair Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides

Also Published As

Publication number Publication date
SK3132001A3 (en) 2001-10-08
LT4959B (lt) 2002-10-25
JP5270594B2 (ja) 2013-08-21
AU755556B2 (en) 2002-12-12
AP2001002108A0 (en) 2001-03-31
CN1316906A (zh) 2001-10-10
CU23251A3 (es) 2007-12-17
EP1112082B1 (en) 2002-07-31
CN100438905C (zh) 2008-12-03
JP2010138186A (ja) 2010-06-24
HRP20010259B1 (en) 2007-11-30
TW574036B (en) 2004-02-01
ES2181473T5 (es) 2010-07-05
JP4557426B2 (ja) 2010-10-06
PT1112082E (pt) 2002-12-31
AR022671A1 (es) 2002-09-04
GEP20032946B (en) 2003-04-25
IS5836A (is) 2001-01-31
DK1112082T3 (da) 2002-11-25
JP2013144691A (ja) 2013-07-25
EA200100337A1 (ru) 2001-10-22
LV12684A (en) 2001-07-20
LT2001041A (en) 2002-06-25
CA2342243C (en) 2014-01-14
NZ509349A (en) 2003-08-29
BG105435A (en) 2001-12-29
AU755556C (en) 2005-12-15
NO20011207L (no) 2001-05-09
EP1112082A2 (en) 2001-07-04
NO328898B1 (no) 2010-06-07
RS50344B (sr) 2009-11-10
NO20011207D0 (no) 2001-03-09
DK1112082T4 (da) 2010-05-31
ZA200101709B (en) 2002-11-28
IL141564A (en) 2009-08-03
AU5821499A (en) 2000-04-03
HUP0103638A3 (en) 2004-06-28
IS2381B (is) 2008-07-15
WO2000015245A3 (en) 2000-06-08
TR200100728T2 (tr) 2001-08-21
DE69902396T2 (de) 2003-03-20
EE200100140A (et) 2002-06-17
JP2007169301A (ja) 2007-07-05
KR20010086388A (ko) 2001-09-10
CA2342243A1 (en) 2000-03-23
HUP0103638A2 (hu) 2002-01-28
ID28824A (id) 2001-07-05
YU19001A (sh) 2005-06-10
PL347069A1 (en) 2002-03-11
ATE221386T1 (de) 2002-08-15
DE69902396D1 (de) 2002-09-05
CO5170497A1 (es) 2002-06-27
EA003367B1 (ru) 2003-04-24
UA72477C2 (uk) 2005-03-15
US8173138B2 (en) 2012-05-08
BG65555B1 (bg) 2008-12-30
JP2002524527A (ja) 2002-08-06
ES2181473T3 (es) 2003-02-16
SI1112082T1 (en) 2002-12-31
AP1591A (en) 2006-03-20
KR100699756B1 (ko) 2007-03-27
HRP20010259A2 (en) 2005-02-28
SK286919B6 (sk) 2009-07-06
SA99200566B1 (ar) 2006-09-20
US20070148189A1 (en) 2007-06-28
SI20566B (sl) 2008-08-31
WO2000015245A2 (en) 2000-03-23
HK1040927A1 (en) 2002-06-28
SI20566A (sl) 2001-12-31
LV12684B (lv) 2001-10-20
PL200926B1 (pl) 2009-02-27
EP1112082B2 (en) 2010-03-17
IL141564A0 (en) 2002-03-10
US7211261B1 (en) 2007-05-01
DE69902396T3 (de) 2010-09-30

Similar Documents

Publication Publication Date Title
BR9913585A (pt) Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável
BR9916879A (pt) Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
SE9404196D0 (sv) New antithrombotic formulation
HU9700056D0 (en) New pharmaceutical composition for treating pains
BR0110420A (pt) Agonistas muscarìnicos
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR9713785A (pt) Composto, uso do mesmo, agente de diagnóstico, composição farmacêutica, e, processos para a preparação de um composto e para o tratamento da dor, de distúrbios gastrointestinais e de lesões na coluna vertebral.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0316906A (pt) administração do capsaicinoides
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0211673A (pt) Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
BR0210057A (pt) Composição compreendendo agentes antifúngicos para tratar vulvovaginite e vaginose
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
BR0317361A (pt) Método de tratamento, prevenção ou inibição de um distúrbio do snc e/ou dor e inflamação utilizando uma associação de duloxetina, venlafaxina ou atomoxetina e um inibidor seletivo da ciclooxigenase-2 e suas formulações
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0204911A (pt) Composição cosmética destinada ao tratamento das fibras queratìnicas humanas que compreende um silicone aminado particular, processo de preparação de uma composição. processo e dispositivo com dois compartimentos ou 'kit' para a descoloração ou a deformação permanente das fibras queratìnicas humanas
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SOLSTICE NEUROSCIENCE, INC. (US)

Free format text: TRANSFERIDO DE: ELAN PHARMACEUTICALS, INC.

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: SOLSTICE NEUROSCIENCES, INC. (US)

Free format text: REFERENTE A RPI 1942 DE 25/03/2008 COD. 25.1, QUANTO AO NOME DO TITULAR ITEM (71).

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.